News

July 15, 2014 — Micell Technologies Inc. announced the United States Patent and Trademark Office (USPTO) has issued a patent related to Micell's technology for enhancing the performance of medical...

A big fly in the ointment for widespread adoption of many new technologies is cost. In today’s cost-conscience environment of healthcare reform, there needs to be a clear, quantifiable...

OrbusNeich Patient Enrollment Completion REMEDEE Registry Combo Stent

OrbusNeich announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal...

June 10, 2014 — Ariad Pharmaceuticals Inc. and Medinol Ltd. earlier this year initiated two registration trials of Medinol’s NIRsupreme ridaforolimus-eluting coronary stent system incorporating...

Boston Scientific Promus Premier Drug Eluting Stent

Boston Scientific Corp. has launched the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System in Japan. This advanced drug-eluting stent (DES) technology system recently...

Biolimus Everolimus Stent Clinical Trial ACC.14

A new stent covered with biodegradable coating continues to show statistical equivalence to Japan’s market leader in cumulative second-year data and subgroup analyses, according to research from...

Medtronic Endeavor Stents Drug-eluting Antiplatelet Therapy Clinical Study

Patients with coronary artery disease who received an Endeavor or Resolute drug-eluting stent from Medtronic Inc. and subsequently interrupted their dual ...

cath lab stents drug eluting boston scientific promus premier

Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval for the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's durable...

A new study demonstrated that some patients may not need to receive prolonged anti-clotting therapy after drug-...

Promus Element, Boston Scientific, Promus Element stent, drug-eluting stent

In the first head-to-head randomized controlled trial of third-generation durable-polymer drug-eluting stents for the treatment of coronary artery disease in an all-comers patient population, the...

xience prime xpedition V antiplatelet stents eluting clinical trial study cath

Abbott announced it plans to initiate a randomized, controlled trial in the United States to evaluate the use...

biotronik orsiro stents drug-eluting cinical trial bioflow

Biotronik Japan announced enrollment of the first patient in the Bioflow-IV study, which aims to verify the efficacy...

stents drug eluting biosensors tct 2012 transcatheter biomatrix neoflex spectrum

Biosensors International’s expanded product portfolio offers physicians a broader range of treatment options to improve patient outcomes.

Patient enrollment has been initiated in a post-market registry for the COMBO Dual Therapy Stent to evaluate its long-term safety and performance in routine clinical practice. The...

Boston Scientific Concludes Evolve II Clinical Trial Enrollment Synergy Stent

In a significant milestone toward obtaining additional key regulatory approvals for the Synergy drug eluting...

Cook Medical is again shipping its Zilver PTX drug-eluting peripheral stent to medical centers in the United States, Japan, Europe and other major markets. The shipments follow a brief period...

Patient enrollment has been initiated in a post-market registry for the Combo Dual Therapy Stent to evaluate its long-term safety and performance in routine clinical practice. The prospective,...

Xience Prime Orsiro Drug Eluting Stent BIO-GLOW II Clinical Study Biotronik Abbo

Primary end-point results from the BIOFLOW-II clinical study demonstrating the non-inferiority of the Biotronik Orsiro Hybrid Drug-Eluting Stent compared to Abbott's Xience Prime. These results...